Conmed Exits Gastroenterology Sector to Concentrate on Core Surgical Markets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Benzinga
CONMED's Strategic Shift: CONMED Corporation is exiting its gastroenterology product lines to focus on higher-growth surgical markets, including minimally invasive and robotic surgery, as part of a portfolio overhaul.
Financial Implications: The exit from gastroenterology is expected to reduce earnings in the short term, with an anticipated EPS dilution of 45 to 55 cents in 2026, but is projected to improve profitability and gross margins in the long run.
Distribution Agreement Termination: The company is ending its exclusive distribution rights for the Gore VIABIL biliary stent earlier than planned, effective January 1, 2026, to streamline its focus on core growth platforms.
2025 Revenue Guidance: Despite the changes, CONMED reaffirmed its 2025 revenue outlook of $1.365 billion to $1.372 billion, with adjusted earnings guidance of $4.48 to $4.53 per share, maintaining alignment with market consensus.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNMD
Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 50.00 USD with a low forecast of 41.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 37.310
Low
41.00
Averages
50.00
High
55.00
Current: 37.310
Low
41.00
Averages
50.00
High
55.00
About CNMD
CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CONMED Corporation Q4 2025 Earnings Call Insights
- Sales Growth: CONMED reported total sales of $373.2 million for Q4 2025, reflecting a year-over-year increase of 7.9%, with full-year sales reaching $1.375 billion, indicating stable growth potential in the medical device market.
- Strategic Shift: The company announced its exit from gastroenterology product lines, which is expected to improve long-term consolidated gross margins by approximately 80 basis points, demonstrating a focus on higher-growth business areas.
- Supply Chain Improvement: In sports medicine, CONMED reported back order values and SKU counts at a three-year low, indicating significant progress in resolving supply chain constraints, which is expected to further drive future performance.
- Future Outlook: Management is guiding for 2026 revenue between $1.345 billion and $1.375 billion, with adjusted EPS between $4.30 and $4.45, reflecting confidence in future growth and a commitment to ongoing investments.
Continue Reading
CONMED (CNMD) Q4 2025 Earnings Call Transcript
Continue Reading